Expert Interview
Looking at the Interim 60-week Results from the SPECTRA Clinical Trial Evaluating Intravitreal 4D-150 in Diabetic Macular Edema
Ticker(s): FDMTInstitution: Rush University & Illinois Retina Associates
- Assistant Professor of Ophthalmology at Rush University Medical Center & co-investigator on several clinical trials.
- Manages 20 patients a week with wAMD.
- Research interests include assessing the color performance of the NGENUITY 3D visualization system and meta-analyses of cytokines in various retinal diseases; clinical focus on the medical and surgical treatment of diseases affecting the retina, vitreous and macula.
Describe your background and practice setting
Added By: nick_adminHow many patients with DME do you currently manage?
Added By: nick_adminCan you describe the standard of care for DME?
Added By: nick_adminWhere will 4DMT’s eye gene therapy fit into your treatment algorithm for DME?
Added By: nick_adminRank your excitement for 4DMT’s eye gene therapy on a scale of 1-10
Added By: nick_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
